|
A.
|
BioZone Phamlaceutical. Inc .. a Delaware corporation having a principal place of business at 580 Garcia Avenue. Pittsburg. CA 94565 ("BPI") is the successor in interest to BioZone Laboratories. Inc. ("BU") and the assignee of the BLI’s entire interest under the Agreement:
|
|
B.
|
BetaZone Laboratories LLC ("BetaZone") has developed the ophthalmic products listed in the attached schedule ("Existing Ophthalmic Products") pursuant to the Agreement: and
|
|
C.
|
BLI wishes to enter into a new separate license agreement relating to ophthalmic products with a third party;
|
|
1.
|
BetaZone shall have the right to continue to market and sell Existing Ophthalmic Products pursuant to the Agreement. Such right shall include all other rights necessary to implement such marketing and sales activity. including the right to continue manufacture of Existing Ophthalmic Products pursuant to the Agreement.
|
|
2.
|
BetaZone shall not develop. market or sell any new therapeutic and/or preventative ophthalmic products incorporating the confidential information and/or Know-How as defined in the Agreement.
|
|
Signed:
|
||
|
/s/ Camillo Rey
|
/s/ Brian Keller
|
|
|
Managing Director
|
CEO
|
|
|
BetaZone
|
BPI
|
|
|
04/04/2011
|
||
|
Date
|
Date
|
|